{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:10:18Z","timestamp":1793729418065,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008485","name":"Schweizerische Akademie der Medizinischen Wissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.radonc.2024.110235","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T02:29:30Z","timestamp":1710815370000},"page":"110235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5330-3820","authenticated-orcid":false,"given":"Sebastian M.","family":"Christ","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-7621","authenticated-orcid":false,"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-6446","authenticated-orcid":false,"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-6834","authenticated-orcid":false,"given":"P\u00e8tra","family":"Braam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Stellamans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-6616","authenticated-orcid":false,"given":"Ivica","family":"Ratosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-6690","authenticated-orcid":false,"given":"Joachim","family":"Widder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-8274","authenticated-orcid":false,"given":"Heike","family":"Peulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-1903","authenticated-orcid":false,"given":"Piet","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-7717","authenticated-orcid":false,"given":"Sara","family":"Ramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-6188","authenticated-orcid":false,"given":"Hossein","family":"Hemmatazad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-130X","authenticated-orcid":false,"given":"Kaouthar","family":"Khanfir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-2597","authenticated-orcid":false,"given":"Xavier","family":"Geets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Jeene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Ivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-2480","authenticated-orcid":false,"given":"Enrico","family":"Clementel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3927-1214","authenticated-orcid":false,"given":"Catherine","family":"Fortpied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Boakye","family":"Oppong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110235_b0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0010","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer Version 4.2022 [Internet]. 2022."},{"key":"10.1016\/j.radonc.2024.110235_b0015","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-Small Cell Lung Cancer Version 3.2022 [Internet]. 2022."},{"key":"10.1016\/j.radonc.2024.110235_b0020","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Kidney Cancer Version 2.2023 [Internet]. 2022."},{"key":"10.1016\/j.radonc.2024.110235_b0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/COC.0000000000000169","article-title":"Definitive stereotactic body radiotherapy (SBRT) for Extracranial Oligometastases","volume":"40","author":"Lewis","year":"2017","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"10.1016\/j.radonc.2024.110235_b0030","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0035","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA","volume":"4","author":"Iyengar","year":"2018","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for Oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0045","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.radonc.2024.110235_b0050","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous Oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110235_b0055","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for Oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol [Internet]"},{"key":"10.1016\/j.radonc.2024.110235_b0060","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized eortc intergroup phase ii study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-019-3837-y","article-title":"Pulmonary Metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial","volume":"20","author":"Treasure","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.radonc.2024.110235_b0075","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0080","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ijrobp.2022.05.023","article-title":"Definitive local consolidative therapy for Oligometastatic solid tumors: results from the Lead-in phase of the randomized basket trial EXTEND","volume":"114","author":"Sherry","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110235_b0085","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy\/ observation for patients with Oligometastatic non-small cell lung cancer without progression after front-line systemic therapy: results of a multi-institutional phase II randomized study","volume":"17","author":"Gomez","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0095","series-title":"Linear mixed models for longitudinal data","author":"Molenberghs","year":"2000"},{"key":"10.1016\/j.radonc.2024.110235_b0100","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple Comparison procedure for Comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.radonc.2024.110235_b0105","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/sim.4780131308","article-title":"Interim analysis: the alpha spending function approach","volume":"13","author":"DeMets","year":"1994","journal-title":"Stat Med"},{"key":"10.1016\/j.radonc.2024.110235_b0110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtho.2019.08.2505","article-title":"Biologically effective dose in stereotactic body radiotherapy and survival for patients with Early-stage NSCLC","volume":"15","author":"Moreno","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2024.110235_b0115","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12885-019-6063-9","article-title":"Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (\u22645 cm)","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110235_b0120","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.21037\/jtd.2019.12.12","article-title":"A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases","volume":"11","author":"Cao","year":"2019","journal-title":"J Thoracic Dis"},{"key":"10.1016\/j.radonc.2024.110235_b0125","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.21037\/tlcr-20-964","article-title":"Current and future research efforts in oligometastatic non-small cell lung cancer\u2014a systematic review","volume":"10","author":"Brand\u00e3o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2024.110235_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12885-019-5362-5","article-title":"The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases","volume":"19","author":"Klement","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110235_b0135","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.ijrobp.2020.11.045","article-title":"The dutch-belgian registry of stereotactic body radiation therapy for liver metastases: clinical outcomes of 515 patients and 668 metastases","volume":"109","author":"M\u00e9ndez Romero","year":"2021","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110235_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the german Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110235_b0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.04.012","article-title":"Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-a pooled analysis of the german working group \u201cstereotactic radiotherapy\u201d","volume":"97","author":"Rieber","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110235_b0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","article-title":"Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis: SBRT for breast cancer oligometastases","volume":"164","author":"Viani","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024001579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:38:51Z","timestamp":1741455531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024001579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"alternative-id":["S0167814024001579"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110235","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110235"}}